Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A three lncRNA set: AC009975.1, POTEH-AS1 and AL390243.1 as nodal efficacy biomarker of neoadjuvant therapy for HER-2 positive breast cancer

ABSTRACT: A three lncRNA set: AC009975.1, POTEH-AS1 and AL390243.1 as nodal efficacy biomarker of neoadjuvant therapy for HER-2 positive breast cancer

PROVIDER: PRJNA780030 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

A three lncRNA set: AC009975.1, POTEH-AS1 and AL390243.1 as nodal efficacy biomarker of neoadjuvant therapy for HER-2 positive breast cancer

Project description:We explored whether lncRNA expression in primary tumor had nodal predicting value for HER-2 positive breast cancer who received neoadjuvant therapy. To explore the differentially expressed lncRNA, six HER2+ fresh core biopsies tissues before NAT were collected (3 tissues from ypT0N0 group and 3 tissues from ypT+N+ group) and subjected to lncRNA microarray. Different lncRNAs (POTEH-AS1, LncRNA-AL390243.1, and lncRNA-AC009975.1 ) were selected by microarray, validated by qPCR,

2021-11-13 | GSE188743 | GEO

RNA-Seq analysis identifies to GATA3-AS1 as a lncRNA associated with resistance to neoadjuvant chemotherapy in locally advanced breast cancer patients

Project description:Purpose: Identified the expression profile of lncRNA associated to neoadjuvant chemotherapy response in 11 tumor of locally advanced breast cancer patients Methods: We implemented the transcriptomic analysis from 11 breast cancer samples by paired-end RNA-Seq, as a case-control study (responders vs nonresponders group). Differential expression analysis for lncRNA and mRNA were made to identify lncRNA as predictive biomarkers. Results: We identified the over-expressed lncRNA GATA3-AS1 in nonresponders group. Additionally, we identified the pathways were differentially expressed lncRNA and mRNA are associated in neoadjuvant chemotherapy response. Conclusion: we propose lncRNA GATA3-AS1 as a potential predictive biomarker for patients with LABC luminal B-like subtype that will not respond to neoadjuvant chemotherapy

2021-07-12 | GSE159448 | GEO

Hsa_circRNA_405159 Is A Novel Biomarker to Evaluate the Efficacy of Neoadjuvant chemoradiotherapy in Rectal Cancer

Project description:Our study was the first to investigate the role of hsa_circ_004119 in RC of NACRT, providing a biomarker about the efficacy of NACRT. Hsa_circRNA_405159 could be the therapeutic target of rectal cancer to improve the efficiency of neoadjuvant chemoradiation.

2021-02-18 | GSE166973 | GEO

LncRNA expression profile is associated with neoadjuvant chemotherapy resistance in luminal B breast cancer

Project description:Purpose: Identified the expression profile of lncRNAs associated to neoadjuvant chemotherapy response in 47 luminal B tumors of locally advanced breast cancer patients Methods: We implemented the transcriptomic analysis from 47 luminal B breast cancer samples by paired-end RNA-Seq, as a case-control study (responders vs nonresponders group). Differential expression analysis for lncRNA and mRNA were made to identify lncRNA as predictive biomarkers. Results: We identified a signature of lncRNAs associated with nonresponders group. Additionally, we identified the pathways were differentially expressed lncRNA and mRNA are associated in neoadjuvant chemotherapy response. Additionally, we proposed the clinical application of lncRNA GATA3-AS1 as a predictive biomarker to neoadjuvant chemotherapy response in luminal B breast cancer patients detected by RNA-ISH. Conclusion: we propose the clinical utility of lncRNA GATA3-AS1 detected by RNA-ISH to identify luminal B breast cancer patients that will not respond to neoadjuvant chemotherapy.

2024-08-27 | GSE270967 | GEO

Hsa_circRNA_405159 Is A Novel Biomarker to Evaluate the Efficacy of Neoadjuvant chemoradiotherapy in Rectal Cancer

Project description:Hsa_circRNA_405159 Is A Novel Biomarker to Evaluate the Efficacy of Neoadjuvant chemoradiotherapy in Rectal Cancer

| PRJNA702500 | ENA

Nodal

Project description:Mus musculus Nodal, nodal [Source:MGI Symbol;Acc:MGI:97359], is differentially expressed in 30 experiment(s);

| ENSMUSG00000037171 | ExpressionAtlas

Nodal

Project description:Mus musculus Nodal, nodal [Source:MGI Symbol;Acc:MGI:97359], is expressed in 19 baseline experiment(s);

| ENSMUSG00000037171 | ExpressionAtlas

NODAL

Project description:Monodelphis domestica NODAL, nodal growth differentiation factor [Source:NCBI gene;Acc:100023464], is expressed in 2 baseline experiment(s);

| ENSMODG00000012158 | ExpressionAtlas

Nodal

Project description:Rattus norvegicus Nodal, nodal growth differentiation factor [Source:RGD Symbol;Acc:1305994], is expressed in 1 baseline experiment(s);

| ENSRNOG00000000556 | ExpressionAtlas

NODAL

Project description:Oryctolagus cuniculus NODAL, nodal growth differentiation factor [Source:HGNC Symbol;Acc:HGNC:7865], is expressed in 1 baseline experiment(s);

| ENSOCUG00000008685 | ExpressionAtlas

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data